曼新妥治疗下肢动脉硬化闭塞症的临床效果分析

目的探讨曼新妥(前列腺素E 1脂微球载体制剂注射液)在下肢动脉硬化闭塞症临床应用的效果、及安全性。方法通过回顾性分析220例下肢动脉硬化闭塞症患者(单纯药物治疗)应用曼新妥治疗后临床症状的改善情况,评估曼新妥治疗外周动脉闭塞性疾病的疗效及临床出现的并发症。结果 220例患者中216例患者临床症状明显改善,治疗前后ABI差异有统计学意义(P<0.05),跛行距离明显改善差异有统计学意义(P<0.05);其中静息痛患者32例,疼痛均明显缓解,糖尿病足患者5例,溃疡明显愈合,其中1例因脑梗加重,转至神经内科治疗,1例因心衰转入ICU治疗,1例因血糖不稳转入内分泌治疗,1例因精神障碍疾病,提前出院。结论曼新妥注射液治疗动脉硬化闭塞症效果显著,安全性好。

Objective To observe the therapeutic and safety of prostaglandin E 1 fat microspheres carrier preparations （Lipo PGE 1） in the treatment of lower limb artherosclerosis obliterans （ASO）. Methods Retrospective analysis of clinical symptom improvement situation by 220 cases of lower limb artherosclerosis obliterans （ASO） （Non operation treatment）. Results In 220 patients, the clinical symptoms of 216 patients improved obviously, ABI has significant improvement after treatment （P〈0.05）. Claudication distance significantly improved （P〈0.05）. 32 patients with rest pain, pain relief was obvious. 5 patients with diabetic foot ulcer and ulcer healing obviously. In 1 cases of cerebral infarction exacerbation, and transferred to the department of internal medicine, 1 cases of heart failure treated in ICU, 1 cases of diabetes into the Department of Endocrinology, 1 patients with mental disorders, and earlier discharge. Conclusion The results of treatment of lower limb arteriosclerosis obliterans by Lipo PGE 1 injection is effective and safety.